Product news

The FDA approved Novo Nordisk's NovoSeven RT (coagulation factor VIIa [recombinant] room temperature stable), the first room temperature stable recombinant product available for the treatment of bleeding episodes in patients with hemophilia with inhibitors. NovoSeven RT is a new formulation of NovoSeven (coagulation factor VIIa [recombinant]).

Warner Chilcott and LEO Pharma announced that the FDA has approved the New Drug Application (NDA) for Taclonex Scalp topical suspension. LEO Pharma submitted the NDA for Taclonex Scalp to the FDA in July 2007. Taclonex Scalp contains a combination of calcipotriene 0.005% and betamethasone dipropionate 0.064% for the treatment of moderate to severe psoriasis vulgaris of the scalp in adults. Taclonex Scalp is called Xamiol outside the US.
You must be a registered member of MMM to post a comment.
close

Next Article in Channel

 

Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.